Phase 3 N=31 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
Binge-Eating Disorder · Obesity
Primary: Binge Eating Frequency (Continuous) — 0.8; 12.1 Eating events/28 days — p=.0002
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=637 A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Geographic Atrophy
Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12 — 1.5579; 1.6512; 1.9692 mm^2 — p=0.0004
Phase 3 N=1,563 Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis
Septic Shock
Primary: Death Before Discharge Home by Day 90 — 14; 14.9 percentage of participants — p=0.61
Phase 3 N=92 Long-Term Treatment With rhIGF-1 in GHIS
Growth Hormone Insensitivity Syndrome
Primary: Annualized Height Velocity Up to 12 Years — 2.6; 8.0; 5.9; 5.5 centimeter per year (cm/y)
Phase 3 N=458 A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Cystic Fibrosis
Primary: Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 435; 75…
Phase 3 N=378 Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Participants With ACC Count = 0 at All Visits From Postoperative Day 8 Through Postoperative Day 15 Without Rescue Medication — 48; 10 Participants — p=<0.001
Phase 3 N=193 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Recurrent Adult Primary Liver Cancer
Primary: Overall Survival — 12.30; 15.85 months — p=0.0554
Phase 3 N=517 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Alopecia Areata
Primary: Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24 — 0.8; 33.0; 38.3 Percentage of participants — p=<0.0001
Phase 3 N=223 Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment — 45; 33 Participants — p=0.013
Phase 3 N=482 A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Migraine · Migraine With Aura · Migraine Without Aura
Primary: Percentage of Participants With Attacks With Sustained Freedom From Headache Pain 2-48 Hours (Modified Intent to Treat Population) — 40.0 Participants
Phase 3 N=264 Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
Relapsing-Remitting Multiple Sclerosis (RRMS)
Primary: Cumulative Number of New Active Lesions Over 24 Weeks — 1.4; 1.9; 1.4; 2.1 lesions
Phase 3 N=131 Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
Actinic Keratosis
Primary: Participant Complete Response Rate (CRR) — 68.4; 6.9 Percentage of participants
Phase 3 N=253 Adolescent Mite Allergy Safety Evaluation
Allergic Rhinitis · Allergic Rhinoconjunctivitis
Primary: Number of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) — 223 subjects
Phase 3 N=64 CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
Hereditary Angioedema
Primary: Time-Normalized Number of Hereditary Angioedema (HAE) Attacks Per Month During Treatment Period — 0.27; 2.01 number of HAE attacks per month — p=<0.001
Phase 3 N=1,559 A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Hyperphosphatemia
Primary: Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder Population — 0.43; 1.80 mg/dL — p=<0.0001